<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03655483</url>
  </required_header>
  <id_info>
    <org_study_id>YH-S001-04</org_study_id>
    <nct_id>NCT03655483</nct_id>
  </id_info>
  <brief_title>Study of GLS-010 Injection in the Treatment of Classical Hodgkin's Lymphoma</brief_title>
  <official_title>A Single Arm，Multicenter， Phase II Clinical Study to Evaluate the Efficacy and Safety of GLS-010 Injection in the Treatment of Recurrent or Refractory Classical Hodgkin's Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guangzhou Gloria Biosciences Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Guangzhou Gloria Biosciences Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with refractory cHL. Patients will be treated with GLS-010
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Open, uncontrolled, multi-center, phase II study.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 24, 2018</start_date>
  <completion_date type="Anticipated">April 11, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 11, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>2 months</time_frame>
    <description>Based on an independent image assessment board</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>8 weeks</time_frame>
    <description>meaningful benefit in PFS based on Lugano 2014</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>within 3 years of last patient enrolled</time_frame>
    <description>Overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DCR</measure>
    <time_frame>8 weeks</time_frame>
    <description>meaningful benefit in DCR based on Lugano 2014</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DOR</measure>
    <time_frame>8 weeks</time_frame>
    <description>meaningful benefit in DOR based on Lugano 2014</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TTR</measure>
    <time_frame>8 weeks</time_frame>
    <description>meaningful benefit in TTR based on Lugano 2014</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">85</enrollment>
  <condition>Classical Hodgkin's Lymphoma</condition>
  <arm_group>
    <arm_group_label>GLS-010</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GLS-010</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GLS-010</intervention_name>
    <description>Full-human anti-pd-1 monoclonal antibodies</description>
    <arm_group_label>GLS-010</arm_group_label>
    <other_name>Full-human anti-pd-1 monoclonal antibodies</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who met all the criteria below could be selected for the study:

               1. Willingness to participate in the clinical trial. Provide written informed
                  consent prior to any study-specific screening procedures. Willingness and
                  capability to comply with the requirements of the study;

               2. Male or female, Age between 18 and 70 years old (margin included) on the day of
                  signing informed consent.

               3. Histologically confirmed diagnosis of cHL(classical Hodgkin Lymphoma);

               4. Relapsed or refractory classical Hodgkin Lymphoma patients after 2 or more lines
                  of therapies( Relapsed cHL patients are defined as patients with new lesion found
                  at primary site or other sites after achieving a complete response after the last
                  treatment; refractory cHL is defined as patients achieve a less than complete
                  response or partial response after the last treatment）and at least one of the
                  following condition is in accordance with:

                    1. Participant has failed to achieve a response after treatment with autologous
                       stem cell transplant (auto-SCT) or relapsed after achieving a response.

                    2. Participant has failed to achieve a response to, progressed after, or be
                       ineligible for autologous stem cell transplant (auto-SCT)

               5. Based on Lugano 2014, at least one bi-dimensional measurable Lymph node lesion
                  with minimum measurement of &gt; 15 mm or an extranodal lesion with minimum
                  measurement of &gt; 10 mm in the longest diameter of cross-sectional areas in CT
                  test, plus positive on Fluorodeoxyglucose-positron tomography（FDG-PET）.

               6. Paraffin embedding sample or biopsy sample available during screening;

               7. Must have ECOG performance status of 0 or 1

               8. Has a predicted survival period ≥ 12 weeks;

               9. Demonstrate adequate organ and hematopoietic function as defined below:

                    1. Hemoglobin ≥8.0 g/dL

                    2. Absolute neutrophil count (ANC) ≥1000 /mcL

                    3. Platelets ≥75,000 / mcL

                    4. Serum total bilirubin ≤ 1.5 X ULN

                    5. AST (SGOT) and ALT (SGPT) ≤ 2.5 X ULN OR ≤ 5 X ULN for subjects with liver
                       metastases

                    6. Serum creatinine OR ≤1.5 X upper limit of normal (ULN)

                    7. International Normalized Ratio (INR) or Prothrombin Time (PT)≤1.5 X ULN
                       unless subject is receiving anticoagulant therapy, then as long as
                       coagulation parameter (PT /INR or Activated Partial Thromboplastin Time
                       (aPTT) , or anti-Xa factor )is within therapeutic range of intended use of
                       anticoagulants.

              10. Since signing the ICF, female or male subjects of childbearing potential should
                  be willing to use an adequate method of contraception with the spouse for the
                  course of the study through 5 months after the last dose of study medication.

        Exclusion Criteria:

          -  Subjects who met the following criteria were not eligible for the study:

               1. Nodular lymphocytes is confirmed as primary Hodgkin lymphoma or grey zone
                  lymphoma.

               2. Has known active central nervous system (CNS) metastases.

               3. Has undergone allogeneic hematopoietic stem cell transplantation.

               4. Has undergone autologous stem cell transplantation within 100 days prior to the
                  first dose of study drug.

               5. Grade 3 or 4 congestive heart failure (New York Heart Association (NYHA)),
                  unstable angina pectoris, poorly controlled arrhythmias(including male QTc
                  intervals≥ 450 ms, female QTc intervals≥ 470 ms, QTc intervals calculated by
                  Formula Fridericia), acute ischemia on ECG or myocardial infarction within 6
                  months prior to screening.

               6. Patients with any autoimmune disease, i.e., but not limited to, interstitial
                  pneumonia, uveitis, enteritis,hypophysitis, vasculitis, nephritis,
                  hyperthyroidism, hypothyroidism (hypothyroidism without clinical symptoms or
                  caused by radiotherapy and chemotherapy can be included); Patients with vitiligo
                  or asthma CR in Childhood, not requiring any intervention in adulthood are
                  permitted to enroll.; patients with asthma requiring a bronchiectasis
                  intervention are not permitted to enroll.

               7. Subjects that requires systemic corticosteroids (Dose equivalent to or above 10
                  mg prednisone daily) or other immunosuppressive medications;

               8. Has received a live anti-tumor vaccine, or anti-tumor treatment with
                  immunostimulation within 4 weeks prior to pre-screening.

               9. Prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137 or anti
                  CTLA-4 antibody (including Ipilimumab or any other antibody or drug specifically
                  targeting T-cell co-stimulation or checkpoint pathways).

              10. Presence of other active cancers within 5 years prior to enrollment. Patients
                  with cervical carcinoma in situ/ cured skin basal cell carcinoma who have
                  received definitive adequate treatment are eligible.

              11. Participants with active viral hepatitis (positive HepB sAg and/or positive HepB
                  core Ab with positive HepB DNA&gt; 103copies/mL, or positive HepC antibody), or
                  syphilis positive.

              12. Has a known Human Immunodeficiency Virus (HIV) infection, or other acquired and
                  congenital immune deficiency diseases, or history of organ transplant.

              13. Has history of active TB infection within 1 year prior to enrollment. (Suspected
                  TB infection patient needs chest X-ray, sputum examination and clinical symptom
                  for conformation. Patients with active TB infection should be excluded even if
                  cured.)

              14. Subject that requires systematic treatment for active infection, unexplained
                  fever&gt; 38.5°C prior to the first dose of study drug during screening( Subjects
                  that has tumor related fever could be included while confirmed by the
                  investigator.)

              15. History of allergic reactions attributed to any macromolecular protein
                  preparation/monoclonal antibody, or any other composition of the study drug.

              16. Investigational drug therapy outside of this trial during or within 4 weeks prior
                  to GLS-010.

              17. Has had prior chemotherapy, radiation therapy, targeted small molecule therapy or
                  major surgery within 4 weeks prior to the first dose of study drug; who has not
                  recovered (i.e. ≤ Grade 1 or at baseline) from adverse events due to a previously
                  administered agent (alopecia excluded)

              18. Has history of Interstitial Lung Disease or non-infectious pneumonitis (Patients
                  caused by radiotherapy are eligible.)

              19. Has history of alcoholism or drug abuse within 1 year;

              20. Has clear history of neurological or mental disorders, i.e. epilepsy, dementia,
                  and poor compliance.

              21. Has received an anti-infection vaccine within 4 weeks prior to the first dose of
                  study drug (i.e. Influenza virus vaccines, HPV vaccines). Any live vaccines are
                  not allowed during the study.

              22. Pregnancy or lactation.

              23. Other conditions that do not permit compliance with the protocol, evaluated by
                  the investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jun Zhu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking University Cancer Hospital &amp; Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yuqin Song, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking University Cancer Hospital &amp; Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Guizhou Cancer Hospital</name>
      <address>
        <city>Guiyang</city>
        <state>Guizhou</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hunan Cancer Hospital</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sichuan Cancer Hospital</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tianjin Cancer Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peking University Cancer Hospital &amp; Institute</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>August 28, 2018</study_first_submitted>
  <study_first_submitted_qc>August 29, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 31, 2018</study_first_posted>
  <last_update_submitted>June 8, 2020</last_update_submitted>
  <last_update_submitted_qc>June 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

